Eli Lilly and Co Q1 2022 Earnings Call Summary - Thomson StreetEvents

Eli Lilly and Co Q1 2022 Earnings Call Summary

Eli Lilly and Co Q1 2022 Earnings Call Summary - Thomson StreetEvents
Eli Lilly and Co Q1 2022 Earnings Call Summary
Published Apr 28, 2022
24 pages (14663 words) — Published Apr 28, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of LLY.N earnings conference call or presentation 28-Apr-22 1:00pm GMT

  
Brief Excerpt:

...A. Highlights: 2022 is off to a strong start with solid volume-driven revenue growth, led by key products and new tirzepatide obesity data Co. announced on 04/28/22. 1. Focused on driving adoption of newer medicines, preparing for key product launches, delivering several global submissions for potential new medicines, all the while advancing pipeline to power the next wave of growth. a. 2. Pleased with progress Co. saw in 1Q. 3. Ukraine office is currently closed and operations are suspended. Safety of employees and their families continues to be top priority. a. b. Working through logistical challenges in order to ensure supply of medicines to those in need in Ukraine. c. Earlier this month, an initial shipment of medicines donated by LLY, including insulin, arrived in Ukraine due to efforts of partners, Project HOPE and Direct Relief. d. Few of Co.'s clinical trial participants are in Ukraine. i. There is minimal impact to global trials. 4. Russia: a. Has suspended investments, promotional...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Eli Lilly and Co
Ticker
LLY.N
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Another one on tirzepatide first. So if the compelling data today enables an earlier filing in obesity, are you also now hoping to secure a quick review? Do you think that, that would -- you would get that as a supplementary filing or perhaps you would look to use the PRV that you purchased this quarter? And can you also just confirm the exact PDUFA date for the diabetes filing? And then my second question for you, Anat, on IPR&D and guidance. Clearly, this cost could evolve [within the year] if you make further acquisitions, collaborations and so on. But can we expect you to provide visibility at the start of each year on what extent or level of milestones you believe are likely to be paid in the years ahead?

Table Of Contents

Eli Lilly and Co at Goldman Sachs Global Healthcare Conference Transcript – 2022-06-14 – US$ 54.00 – Edited Transcript of LLY.N presentation 14-Jun-22 5:40pm GMT

Eli Lilly and Co Diabetes & Obesity Update at ADA Call Transcript – 2022-06-07 – US$ 54.00 – Edited Transcript of LLY.N conference call or presentation 7-Jun-22 3:30pm GMT

Eli Lilly and Co at UBS Global Healthcare Conference Transcript – 2022-05-24 – US$ 54.00 – Edited Transcript of LLY.N presentation 24-May-22 12:30pm GMT

Eli Lilly and Co at Bank of America Healthcare Conference Transcript – 2022-05-10 – US$ 54.00 – Edited Transcript of LLY.N presentation 10-May-22 11:40pm GMT

Eli Lilly and Co Q1 2022 Earnings Call Transcript – 2022-04-28 – US$ 54.00 – Edited Transcript of LLY.N earnings conference call or presentation 28-Apr-22 1:00pm GMT

Eli Lilly and Co at Barclays Global Healthcare Conference Transcript – 2022-03-15 – US$ 54.00 – Edited Transcript of LLY.N presentation 15-Mar-22 2:15pm GMT

Eli Lilly and Co at Cowen Health Care Conference (Virtual) Transcript – 2022-03-08 – US$ 54.00 – Edited Transcript of LLY.N presentation 8-Mar-22 3:30pm GMT

Eli Lilly and Co at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript – 2022-02-09 – US$ 54.00 – Edited Transcript of LLY.N presentation 9-Feb-22 5:00pm GMT

Eli Lilly and Co Q4 2021 Earnings Call Summary – 2022-02-03 – US$ 54.00 – Edited Brief of LLY.N earnings conference call or presentation 3-Feb-22 2:00pm GMT

Eli Lilly and Co Q4 2021 Earnings Call Transcript – 2022-02-03 – US$ 54.00 – Edited Transcript of LLY.N earnings conference call or presentation 3-Feb-22 2:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Eli Lilly and Co Q1 2022 Earnings Call Summary" Apr 28, 2022. Alacra Store. May 14, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2022-Eli-Lilly-and-Co-Earnings-Call-B15014209>
  
APA:
Thomson StreetEvents. (2022). Eli Lilly and Co Q1 2022 Earnings Call Summary Apr 28, 2022. New York, NY: Alacra Store. Retrieved May 14, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2022-Eli-Lilly-and-Co-Earnings-Call-B15014209>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.